An Eight-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled Dose-Finding Study, With Escitalopram (10 mg Daily) as Active Control, to Evaluate the Efficacy, Safety and Tolerability of Three Fixed Doses of SSR411298 (10, 50, or 200 mg Daily) in Elderly Patients With Major Depressive Disorder.

Trial Profile

An Eight-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled Dose-Finding Study, With Escitalopram (10 mg Daily) as Active Control, to Evaluate the Efficacy, Safety and Tolerability of Three Fixed Doses of SSR411298 (10, 50, or 200 mg Daily) in Elderly Patients With Major Depressive Disorder.

Completed
Phase of Trial: Phase II

Latest Information Update: 14 Mar 2013

At a glance

  • Drugs SSR 411298 (Primary) ; Escitalopram
  • Indications Major depressive disorder
  • Focus Therapeutic Use
  • Acronyms FIDELIO
  • Most Recent Events

    • 12 Mar 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 21 Jan 2010 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 21 May 2009 Additional location (Ukraine) identified as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top